Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Cash from Investing Activities (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Cash from Investing Activities readings, the most recent being -$2.1 million for Q1 2026.

  • Quarterly Cash from Investing Activities fell 131.92% to -$2.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$10.9 million through Mar 2026, down 199.54% year-over-year, with the annual reading at -$2.2 million for FY2025, 125.6% down from the prior year.
  • Cash from Investing Activities hit -$2.1 million in Q1 2026 for DiaMedica Therapeutics, down from $8.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $9.0 million in Q2 2025 and bottomed at -$28.1 million in Q2 2023.
  • Average Cash from Investing Activities over 5 years is -$147235.3, with a median of $2.5 million recorded in 2022.
  • The largest annual shift saw Cash from Investing Activities soared 24700.0% in 2022 before it crashed 1212.66% in 2023.
  • DiaMedica Therapeutics' Cash from Investing Activities stood at $4.7 million in 2022, then grew by 29.64% to $6.1 million in 2023, then dropped by 15.01% to $5.2 million in 2024, then surged by 53.6% to $8.0 million in 2025, then crashed by 126.44% to -$2.1 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Cash from Investing Activities are -$2.1 million (Q1 2026), $8.0 million (Q4 2025), and -$25.8 million (Q3 2025).